Log in
Enquire now
‌

US Patent 10858339 Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Patent 10858339 was granted and assigned to Aerie Pharmaceuticals on December, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Aerie Pharmaceuticals
Aerie Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10858339
Date of Patent
December 8, 2020
Patent Application Number
15941993
Date Filed
March 30, 2018
Patent Citations
‌
US Patent 10112920 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
0
‌
US Patent 10174017 Dual mechanism inhibitors for the treatment of disease
Patent Citations Received
‌
US Patent 12018012 Aryl cyclopropyl-amino-isoquinolinyl amide compounds
0
‌
US Patent 11312700 Aryl cyclopropyl-amino-isoquinolinyl amide compounds
‌
US Patent 11427563 Aryl cyclopropyl-amino-isoquinolinyl amide compounds
0
‌
US Patent 11891376 Aryl cyclopropyl-amino-isoquinolinyl amide compounds
0
‌
US Patent 11590123 Ophthalmic compositions
‌
US Patent 11618748 Dual mechanism inhibitors for the treatment of disease
0
‌
US Patent 11707460 Ophthalmic compositions
0
Patent Primary Examiner
‌
John S Kenyon
No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10858339 Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.